Lv41
710 积分 2020-10-02 加入
Bispecific and multispecific antibodies in oncology: opportunities and challenges
36分钟前
已完结
FDA approves 100th small-molecule kinase inhibitor
37分钟前
已完结
Key insights from ESMO Congress 2025
38分钟前
已完结
Rational combination of cancer therapies with PD1 axis blockade
2个月前
已完结
Rational combinations of targeted cancer therapies: background, advances and challenges
2个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2个月前
已完结
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
2个月前
已完结
Multiplicity Control in Clinical Trials
3个月前
已完结
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
3个月前
已完结
Trends in the approval of cancer therapies by the FDA in the twenty-first century
3个月前
已完结
皖公网安备34019202002308
